Donanemab is not a cure and comes with significant side effects, but patients had longer periods of independent living while on the drug.
Category: Drugs (Pharmaceuticals)
-
National Academies Members Demand Answers About Sacklers’ Donations
The Academies accepted millions of dollars from members of the Sackler family — including some who led Purdue Pharma, makers of OxyContin — even while advising federal officials on opioid policy.
-
F.D.A. Approves Drug for Rare Form of A.L.S.
The drug, which will be sold as Qalsody by the pharmaceutical company Biogen, targets a genetic cause of a devastating neurological illness.
-
The Fight Over a Drug That Is Great for Horses but Horrific for Humans
Drug dealers are mixing xylazine, an animal tranquilizer relied on by veterinarians, into fentanyl, with deadly results. But controlling it is tricky.
-
Abortion Pill Maker Sues F.D.A. to Protect Drug if a Court Orders It Off the Market
The suit by GenBioPro, the generic maker of mifepristone, is the latest strand in the intense legal battle over abortion pills.
-
Insurers Are Starting to Cover Telehealth Abortion
Several insurers will cover abortions through Hey Jane, a start-up online provider, just as courts threaten to hobble the industry.
-
Virtual Clinics Have Been a Fast-Growing Method of Abortion. That Could Change.
So far, most telemedicine providers seem undaunted by court rulings that could imperil their business.
-
Appeals Court Says Abortion Pill Can Remain Available but Imposes Temporary Restrictions
The judges blocked the drug from being sent to patients through the mail and rolled back other steps the government had taken to ease access.
-
Pfizer CEO and Other Drug Company Leaders Condemn Texas Abortion Pill Ruling
More than 250 executives said that the decision ignored both scientific and legal precedent and, if it stands, would create uncertainty for the pharmaceutical and biotech industries.
-
Abortion Ruling Could Undermine the F.D.A.’s Drug-Approval Authority
Legal scholars say the ruling by a Texas judge, if upheld, could spur disputes over many medications and upend the drug industry’s reliance on the agency.
-
Johnson & Johnson Reaches $8.9 Billion Talc Settlement
The company faces a flood of lawsuits claiming its talc products caused cancer. The proposed settlement requires approval by a bankruptcy court, but has the backing of plaintiffs’ lawyers.